Related Experiment Video
Updated: Feb 11, 2026
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized,
Tomoko Hasunuma1, Michio Yagi2, Noboru Nakamichi3
1Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Background:
This first-in-human study compared the pharmacokinetics, safety, and immunogenicity of candidate biosimilar CT-P55 to both European Union (EU)-approved and United States (US)-licensed secukinumab in healthy participants.
Research Design And Methods:
Three-arm, double-blinded, parallel-group, single-dose, Phase 1 study conducted across four centers in Japan over 22 weeks. Healthy adult males were randomized (1:1:1) to a single 150-mg subcutaneous dose of CTP55, EU-approved, or US-licensed secukinumab. Primary endpoints were area under the concentration-time curve from time zero to infinity (AUC0-inf) and maximum serum drug concentration (Cmax).
Results:
Baseline characteristics were comparable across groups (CT-P55 [n = 57], EU-approved secukinumab [n = 59], and US-licensed secukinumab [n = 56]). The 90% confidence intervals for the geometric least squares mean ratios of AUC0-inf and Cmax were within the equivalence margin (80-125%). Safety profiles were comparable. 218 treatment-emergent adverse events were reported for 110 (65.5%) participants; most were Grade 1/2. One serious adverse event was reported (US-licensed secukinumab group). The low immunogenic profile of CT-P55 was comparable to both reference secukinumab groups, with no neutralizing antibodies detected.
Conclusions:
CT-P55 exhibited equivalent pharmacokinetics as well as comparable safety and immunogenicity to both EU-approved and US-licensed secukinumab in healthy Japanese males. Generalizability may be limited beyond Asian males.
Trial Registration:
The study is registered at Clinicaltrials.gov (NCT07054970).
More Related Videos
08:09Use of an Eight-arm Radial Water Maze to Assess Working and Reference Memory Following Neonatal Brain Injury
Published on: December 4, 2013
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Related Concept Videos
02:07Blind Procedures
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
01:28Inductance: Single-Phase And Three-Phase Line
Single-Phase Two-Wire Line:
A single-phase line consists of two solid cylindrical conductors, denoted as x and y. Each conductor carries phasor currents ix and iy, respectively. Given that the sum of these currents is...
01:25Capacitance: Single-Phase And Three-Phase Line
Single-Phase Lines
Consider a single-phase, two-wire transmission line with equal phase spacing energized by a voltage source. One conductor carries a uniform positive charge, while the other carries an equal negative charge. The capacitance C of the line can be derived from the voltage V between the conductors. For a one-meter section of the line, the capacitance is given...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...